All relevant data are within the manuscript and Supporting Information files.

Introduction {#sec005}
============

There is an increasing awareness of the negative effects of blood products in cancer treatment \[[@pone.0205712.ref001]\]. Once considered as a benign intervention, perioperative blood transfusion (PBT) is nowadays recognized as a measure that should be avoided if possible. Seemingly purified products like red blood cell (RBC) suspensions contain variable contents of other blood cells and biologically active compounds \[[@pone.0205712.ref002], [@pone.0205712.ref003]\]. Several processes that occur during and after transfusion are discussed as causes for its adverse effects in surgical oncology. As reviewed by Cata *et al*., these mechanisms include immunosuppression induced by and inflammatory response to PBT. Before routine depletion of leucocytes, post-transfusion infections and febrile reactions were common adverse events \[[@pone.0205712.ref004]\]. By leucoreduction, the release of bioactive substances from white blood cells can largely be avoided. Nevertheless, several actives cytokines are still present in stored erythrocyte units \[[@pone.0205712.ref005]\]. Units of red blood cells also contain lipids and a variety of pro-inflammatory mediators like phosphatidylcholines and eicosanoids, as well as microparticles containing numerous growth factors \[[@pone.0205712.ref006], [@pone.0205712.ref007], [@pone.0205712.ref008]\]. The immunomodulatory effects of allogeneic blood transfusions include a decrease of interleukin 2 secretion, a diminished activity of natural killer cells and macrophages, as well as hypersensitivity reaction. PBT can undoubtedly save lifes. On the other hand, mounting evidence shows that it negatively affects patient\`s immune surveillance of cancer and promotes tumor growth and dissemination \[[@pone.0205712.ref004], [@pone.0205712.ref008]\].

Numerous systematic reviews and meta-analyses prove the adverse influence of PBT on outcomes in literally all solid cancers including cholangiocarcinoma, liver, bladder, pancreatic, gastric and lung cancer \[[@pone.0205712.ref009]--[@pone.0205712.ref014]\]. However, much less is known about PBT\`s role in head and neck squamous cell carcinoma (HNSCC). In contrast to, for example, hepatectomy, intra- and perioperative blood transfusions are relatively rare events in the surgical treatment of HNSCC. Still, preoperative anemia is common among HNSCC patients. Anemic conditions before treatment may be attributed to the disease itself, impaired dietary intake and comorbid conditions of HNSCC patients \[[@pone.0205712.ref015]--[@pone.0205712.ref017]\].

We recently described the negative impact of anemia on prognosis of oropharyngeal cancer patients \[[@pone.0205712.ref018]\]. In this localization two distinct HNSCC entities need to be distinguished. On one hand there are "classic" carcinomas linked to tobacco and alcohol consumption and with a peak onset within the 6^th^ decade of life. Affected patients often show a variety of comorbid diseases associated with the respective noxious agents and age. On the other hand an increasing number of oropharyngeal carcinomas are caused by a persistent infection with high-risk human papilloma viruses (HPV). Affected patients are often younger, have no or a limited smoking history and, therefore, less comorbid diseases. Clinically, HPV-associated HNSCC in the oropharynx are identified by positive immunohistochemical staining of p16, a cell cycle regulator that accumulates within cancer cells in the course of HPV-driven carcinogenesis. Despite being less differentiated and showing more advanced cervical lymph node metastasis, HPV-/p16-positive HNSCC are characterized by a remarkably improved therapeutic response and patient\`s survival. Less exposure to tobacco-contained carcinogens, less genetic mutations and better overall health are discussed as major contributors to favorable prognosis. Distinct etiology, tumor biology and therapeutic response led to the acknowledgement of p16-positive oropharyngeal squamous cell carcinomas as a discrete cancer entity in the head and neck with a separate clinical staging system valid since January 2017 \[[@pone.0205712.ref019], [@pone.0205712.ref020]\]

For this study we extended the cohort and included patients who received PBT during their stay at our department. The aim of the study was to confirm our previous results regarding the prognostic effects of anemia in HNSCC and to evaluate the impact of PBT on survival in these patients.

Methods {#sec006}
=======

We retrospectively included 354 patients who underwent surgical resection of their HNSCC at the Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University (LMU), Munich, between January 2006 and October 2016. For this period we obtained a list of patients from our controlling department who were administered blood products. This list was then matched with our blood bank to identify patients who received PBT. All clinical data was obtained from paper based and digital patient files. Follow up data was recorded during posttherapeutic visits and from The Munich Cancer Registry. Clinical data was initially collected without involving the ethics committee, LMU, Munich. After subsequent consultation, the committee stated that patients are not required to sign an informed consent and endorses the publication of the manuscript. A minimal, fully anonymized set of clinical data is available as supporting information.

The *World Health Organization* (WHO) defines anemia as "*a condition in which the number of red blood cells or their oxygen-carrying capacity is insufficient to meet physiologic needs*, *which vary by age*, *sex*, *altitude*, *smoking*, *and pregnancy status"* (<http://www.who.int/topics/anaemia/en/>). The *WHO Global Database on Anemia* reports on the worldwide prevalence of anemia based on hemoglobin concentration. We used both, red blood cell counts (RBC) and hemoglobin-concentration to define anemic conditions as:

1.  RBC \<4.3T/l in women and \<4.8T/l in men, **and/or**

2.  hemoglobin-concentration \<12 g/dL in women and \<14 g/dL in men

Although the WHO uses a worldwide threshold of 13 g/dL for men \>15 years of age below which the individual is considered to be anemic, the medical center of Ludwig-Maximilians-University Munich applies the local population based threshold of 14 g/dl for adult men \[[@pone.0205712.ref021]\]. The hemoglobin threshold that triggers blood transfusion in head and neck surgical oncology is 7 g/dl unless comorbid diseases require other measures. Therefore, our clinic pursues a restrictive transfusion policy \[[@pone.0205712.ref022]\].

Erythrocytes concentrates transfused within the observation time were obtained from the *Bavarian Red Cross*, Munich, Germany or from the *Institute for Transfusion Medicine*, Suhl, Germany. The major additive during a maximum storage period of 49 days was mannitol. All erythrocyte concentrates/units of packed red blood cells underwent leucocyte depletion before storage.

The perioperative period was defined as the timespan between inpatient admission before surgery and discharge from our department. Disease free survival was defined as the time span between surgery and disease recurrence (local and/or regional and/or distant, as well as second primary carcinomas) or death of any cause. Overall survival was defined as the period of time between cancer resection and death of any cause.

Statistical analysis was performed using IBM SPSS Statistics, version 24. p-level was set to 0.05. To test relations between nominal and ordinal scaled factor, the chi square test was applied. Metric scaled variables were tested using the Mann-Whitney-U test. Survival estimates were produced with the Kaplan-Meier method. Significant differences were calculated using log rank test in univariate and cox regression for multivariate analysis. The number of variables included for multivariate analysis were restricted to 1 per 10 events. For this purpose we selected the most significant factors in univariate analysis.

For manuscript writing we tried to adhere to *The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement*: *guidelines for reporting observational studies* \[[@pone.0205712.ref023]\].

Results {#sec007}
=======

354 cases were included. Patient and tumor data are summarized in [Table 1](#pone.0205712.t001){ref-type="table"}. All patients underwent surgical resection of their carcinoma with or without free flap reconstruction, 343 received uni- or bilateral neck dissection. 258 patients were treated with adjuvant (chemo)radiotherapy following surgery. To avoid bias regarding intraoperative blood loss, we excluded tumor resection carried out with lasermicrosurgery. Thus, only total laryngectomies were included.

10.1371/journal.pone.0205712.t001

###### Clinical data.

![](pone.0205712.t001){#pone.0205712.t001g}

                                                                                                      n (%)
  -------------------------------------------------------- ------------------------------------------ -------------
  ***Preoperative anemia***                                yes                                        154 (43.5%)
                                                           no                                         200 (56.5%)
  ***Perioperative blood transfusion***                    yes                                        65 (18.4%)
                                                           no                                         289 (81.6%)
  ***Age***                                                \<60                                       171 (48.3%)
                                                           ≥60                                        183 (51.7%)
  ***ASA (physical status)***                              ASA1                                       19 (5.4%)
                                                           ASA2                                       152 (42.9%)
                                                           ASA3                                       179 (50.6%)
                                                           ASA4                                       1 (0.3%)
                                                           N/A                                        3 (0.8%)
  ***Smoking***                                            current                                    187 (52.8%)
                                                           former                                     77 (21.8%)
                                                           never                                      75 (21.2%)
                                                           N/A                                        15 (4.2%)
  ***Localization***                                       oral cavity                                93 (26.3%)
                                                           oropharynx                                 221 (62.4%)
                                                           hypopharynx                                34 (9.6%)
                                                           larynx                                     6 (1.7%)
  ***pT-stage***[^1^](#t001fn001){ref-type="table-fn"}     pT1                                        95 (26.8%)
                                                           pT2                                        145 (41.0%9
                                                           pT3                                        90 (25.4%)
                                                           pT4a                                       24 (6.8%)
  ***pN-stage***[^1^](#t001fn001){ref-type="table-fn"}     pN0                                        126 (35.6%)
                                                           pN1                                        55 (15.5%)
                                                           pN2a                                       28 (7.9%)
                                                           pN2b                                       80 (22.6%)
                                                           pN2c                                       49 (13.8%)
                                                           pN3                                        5 (1.4%)
                                                           pNx                                        11 (3.1%)
  ***UICC-stage***[^1^](#t001fn001){ref-type="table-fn"}   I                                          47 (13.3%)
                                                           II                                         53 (15.0%)
                                                           III                                        97 (27.4%)
                                                           IVA                                        141 (39.8%)
                                                           IVB                                        4 (1.4%)
                                                           N/A                                        11 (3.1%)
  ***p16***                                                positive                                   71 (20.1%)
                                                           negative                                   87 (24.6%)
                                                           N/A                                        201 (55.4%)
  ***Perineural invasion***                                Pn0 (absent)                               106 (29.9%)
                                                           Pn1 (present)                              33 (9.3%)
                                                           N/A                                        139 (39.3%)
  ***Lymphovascular invasion***                            L0 (absent)                                113 (31.9%)
                                                           L1 (present)                               68 (19.2%)
                                                           N/A                                        173 (48.9%)
  ***Vein invasion***                                      V0 (absent)                                166 (46.9%)
                                                           V1 (present)                               12 (3.4%)
                                                           N/A                                        176 (59.7%)
  ***Extranodal extension***                               ENE-                                       63 (17.8%)
                                                           ENE+                                       58 (16.4%)
                                                           N0[^2^](#t001fn002){ref-type="table-fn"}   126 (35.6%)
                                                           N/A                                        107 (30.2%)
  ***Grading***                                            G1                                         24 (6.8%)
                                                           G2                                         134 (37.9%)
                                                           G3                                         196 (55.4%)
  ***Adjuvant treatment***                                 yes                                        258 (72.9%)
                                                           no                                         95 (26.8%)
                                                           N/A                                        1 (0.3%)

^1^ Union International contre le Cancre (UICC), Staging Manual, 7^th^ edition;

^2^ clinically or pathologically N0

In accordance to what is currently known about p16-negative and -positive HNSCC, all 71 p16-positive tumors were located in the oropharynx. Patients with p16-positive tumors were less often current smokers (30.9% vs. 65.9%; p\<0.001). p16-positive cancers were less differentiated (G3: 83.1% vs. 54.0%; p\<0.001) and had more often spread to cervical lymph nodes (pN+: 84.5% vs. 61.4%; p = 0.001). No difference between p16-positive and -negative cases was found regarding age and preoperative assessment of physical status according to the *American Society of Anesthesiologists* (ASA).

Anemia {#sec008}
------

Preoperative blood samples were taken at least 10 days before surgery. Mean RBC was 4.50 T/l (median: 4.53; range: 2.32--5.81), mean hemoglobin concentration 13.99 g/dl (median: 14.2; range: 8.0--17.8). A total of 154 patients (43.5%) were found to be anemic. 70 patients had low hemoglobin level and low RBC counts. 9 patients had low hemoglobin concentrations, but normal RBC counts. 75 patients were classified as anemic because of low RBC counts only.

Anemic conditions were independent from gender, age, ASA-classification, pathological tumor (pT-), pathological lymph node (pN-) stage and prognostic stage group as defined by the *Union Internationale Contre le Cancre* (UICC). Current (49.7%) or former smokers (41.6%) at the time of diagnosis were more often anemic compared to never smokers (25.3%; p = 0.001). Hence, patients diagnosed with HPV-associated, p16-positive HNSCC suffered less often from anemic conditions than p16-negative cases (26.8% vs. 60.9%; p\<0.001).

Perioperative blood transfusion (PBT) {#sec009}
-------------------------------------

65 patients (18.4%) received at least one PBT. In 24 of these cases (36.9%) a postoperatively developing or increasing anemia without any apparent cause was corrected. 23 patients (35.4%) received PBT during initial tumor resection or during revision surgery. In 12 cases (18.5%) at least one erythrocyte concentrate was transfused in response to postoperative bleeding. 6 patients (9.2%) needed blood transfusion(s) in the course of measures unrelated to the tumor resection. For instance, two patients suffered a postoperative myocardial infarction and needed PBT to support coronary perfusion. One patient received a total of 45 erythrocytes transfusions in the course of a fulminant deep vein thrombosis that finally led to leg amputation. A total of 11 patients received platelet concentrates only (1 patient), fresh frozen plasma only (5 patients), or a combination of both (5 patients) in addition to erythrocyte concentrates. 56.9% of transfused patients received 1--2 erythrocyte concentrates, the median amount was 2.0 units per patient (range: 1--45; average: 4.9).

The need for PBT was independent from gender. Patients who received PBT were older (62.6 vs. 59.7 years; p = 0.021) and in worse physical condition. Whereas only 4.1% of patients classified as ASA1/2 were given PBT, this rate was 31.7% in ASA3/4-patients (p\<0.001). No correlation was found with smoking habits. PBT was given less often to preoperatively non-anemic patients (10.5% vs. 28.6%; p\<0.001) and more often to patients with p16-negative HNSCC (33.3% vs. 16.9%; p = 0.019). Furthermore, patients with advanced pT- and pN-stages received more frequently PBT (pT1-2 vs. pT3-4a: 12.9% vs. 29.8%; p\<0.001; pN0-pN2b vs. pN2c-pN3: 14.5% vs. 25.9%; p = 0.038). Transfusion rate was, thus, 7.0% for UICC-stage I /II- and 20.2% in UICC-stage III-IVb-patients (p = 0.001).

Survival analysis {#sec010}
-----------------

All factors shown in [Table 1](#pone.0205712.t001){ref-type="table"} were submitted to uni- and multivariate analysis of disease free (DFS) and overall survival (OS; [Table 2](#pone.0205712.t002){ref-type="table"}). We recorded 128 recurrences, 126 patients died. Thus, factors included in multivariate analysis of DFS and OS were restricted to 13 (1 variable per 10 events).

10.1371/journal.pone.0205712.t002

###### Survival analysis (entire cohort).

![](pone.0205712.t002){#pone.0205712.t002g}

  --------------------------------- ------------ ---------------------------- -------------------------------
  **Disease free survival**                                                   

                                                 univariate\                  multivariate\
                                                 (log rank test)              (cox regression)

                                    n/censored   p                            p

  Preoperative anemia               354/226      **0.043**                    0.792

  Perioperative blood transfusion   354/226      0.137                        0.496

  Age                               354/226      0.182                        0.427

  ASA                               351/225      0.297                        0.619

  Smoking                           339/217      0.628                        \-

  Localization                      354/226      **0.002**                    0.055

  pT-stage                          354/226      0.059                        **0.029**

  pN-stage                          343/223      **0.033**                    0.566

  UICC                              343/223      0.825                        \-

  p16                               158/118      **0.016**                    0.525

  Perineural invasion               139/105      **0.002**                    0.124

  Lymphovascular invasion           181/134      0.438                        0.365

  Vein invasion                     178/131      0.358                        0.561

  Extranodal extension              121/89       0.077                        0.588

  Grading                           354/226      0.816                        \-

  Adjuvant treatment                353/225      **0.032**                    0.957

  **Overall survival**                                                        

                                                 univariate (log rank test)   multivariate (cox regression)

                                    n/censored   p                            p

  Preoperative anemia               354/226      **\<0.001**                  0.663

  Perioperative blood transfusion   354/226      **\<0.001**                  0.363

  Age                               354/226      **0.001**                    0.296

  ASA                               351/225      **0.027**                    0.778

  Smoking                           339/217      0.155                        0.422

  Localization                      354/226      **0.007**                    **0.014**

  pT-stage                          354/226      0.102                        0.952

  pN-stage                          343/223      **\<0.001**                  0.598

  UICC                              343/223      **0.041**                    0.449

  p16                               158/118      **0.006**                    0.404

  Perineural invasion               139/105      **\<0.001**                  **0.009**

  Lymphovascular invasion           181/134      0.112                        \-

  Vein invasion                     178/131      **0.019**                    0.859

  Extranodal extension              121/89       0.078                        0.330

  Grading                           354/226      0.985                        \-

  Adjuvant treatment                353/225      0.240                        \-
  --------------------------------- ------------ ---------------------------- -------------------------------

Even though preoperative anemia influenced DFS, there were more significant factors in univariate analysis. In multivariate analysis only pT-stage remained significant. Both, preoperative anemia and PBT were highly significant for OS in univariate analysis. Also, pN-stage and perineural invasion showed comparable significance. Whereas pretreatment anemia and PBT lost significance in multivariate analysis, perineural invasion emerged as the most significant factor for OS.

To emphasize the effects of preoperative anemia and PBT we build four classes ([Fig 1](#pone.0205712.g001){ref-type="fig"}):

A.  Preoperatively non-anemic patients, no transfusion (n = 179)

B.  Preoperative non-anemic patients, perioperative transfusion (n = 21)

C.  Preoperative anemic patients, no transfusion (n = 110)

D.  Preoperative anemic patients, perioperative transfusion (n = 44)

![Kaplan-Meier-plots of overall survival of: A: preoperatively non-anemic, not transfused patients. B: preoperatively non-anemic, transfused patients. C: preoperatively anemic, not transfused patients. D: preoperatively anemic, transfused patients.](pone.0205712.g001){#pone.0205712.g001}

Preoperatively non-anemic patients had a significantly better OS compared to non-anemic patients who received PBT (A vs B, p = 0.0179), to anemic patients without PBT (A vs C, p = 0.002) and to anemic patients who needed PBT (A vs D, p\<0.001). No statistical difference in OS was found between transfused non-anemic patients and anemic patients without PBT (B vs C, p = 0.687) and transfused anemic patients (B vs. D, p = 0,189), respectively. Moreover, anemic patients who received PBT had a significantly worse OS compared to anemic patients who were not transfused (C vs. D, p = 0.021).

As stated before, PBT was more frequently administered to older patients, patients in worse physical conditions, anemic patients, patients with p16-negative HNSCC and patients with more advanced pT- and pN-stage HNSCC. Because all these factors are major determinants of OS, we did an analysis of the influence of PBT on OS in 6 subgroups: In patients \<60 years of age, in patients classified as ASA1 or 2, in non-anemic patients, in patients with p16-positive HNSCC and in patients with pT1-2 and pN0-2b HNSCC, respectively. Aside from ASA1 & 2-patients PBT led to a significantly worse survival in all these subgroups ([Table 3](#pone.0205712.t003){ref-type="table"}).

10.1371/journal.pone.0205712.t003

###### Overall survival (OS) in subgroups.

![](pone.0205712.t003){#pone.0205712.t003g}

  Subgroup             PBT                 OS (95% CI) \[years\]   p (log rank test)
  -------------------- ------------------- ----------------------- -------------------
  Age \< 60            no                  7.03 (6.25--7.81)       **\<0.001**
  yes                  2.98 (1.71--4.24)                           
  ASA1 & 2             no                  6.93 (6.22--7.64)       0.365
  yes                  5.01 (2.55--7.48)                           
  Normemic patients    no                  7.35)6.64--8.07)        **0.017**
  yes                  4.16 (2.95--5.38)                           
  p16-positive HNSCC   no                  6.04 (5.47--6.62)       **0.042**
  yes                  3.80 (2.71--4.89)                           
  pT1 & 2              no                  6.93 (6.27--7.59)       **\<0.001**
  yes                  3.31 (2.36--4.26)                           
  pN0-2a               no                  6.97 (6.36--7.59)       **0.029**
  yes                  4.23 (3.29--5.17)                           

OS depending on hemoglobin and RBC status is shown in a separated figure ([Fig 2](#pone.0205712.g002){ref-type="fig"}).

![Kaplan-Meier-plots of overall survival depending on hemoglobin-levels and red blood cell (RBC)-counts.](pone.0205712.g002){#pone.0205712.g002}

Discussion {#sec011}
==========

Approximately 40% of all cancer patients are anemic at diagnosis. Hence, anemia is the most common paraneoplastic syndrome. The causes of anemia in cancer include tumor-triggered formation of antibodies leading to autoimmune hemolysis. Antibodies may also suppress erythropoietin-induced RBC production causing pure red-cell aplasia. In some advanced malignancies physically injured erythrocytes, as a consequence of vascular damage and activation of coagulation by the tumor, die prematurely, causing microangiopathic hemolytic anemia. The commonest type of cancer-associated anemia and anemic conditions caused by other chronic diseases is defined by impaired iron metabolism. As a consequence of the increased expression of hepcidin, a type II acute-phase reactant, intestinal iron absorption and iron release from macrophages is downregulated. This leads to a functional iron deficiency that worsens low nutritional iron intake often seen in HNSCC patients \[[@pone.0205712.ref024]--[@pone.0205712.ref026]\]. Tobacco consumption, still the leading cause of carcinogenesis in the head and neck and comorbid diseases in HNSCC patients, may initially counterbalance paraneoplastic anemia due to the effects of chronic carbon monoxide exposure, but cigarette smoke is also linked to hemolysis, aplastic anemias and hematotoxicity itself \[[@pone.0205712.ref016]\]. As reported previously, the impact of smoking on anemia in HNSCC patients, can be demonstrated comparing patients diagnosed with p16-negative to patients suffering from p16-positive oropharyngeal carcinomas. Significantly less tobacco consumption in the latter group leads to significantly less comorbidities and, thus, to significantly less anemic conditions \[[@pone.0205712.ref018]\]. Accordingly, these patients are less likely to receive PBT.

Anemia is an independent prognostic factor in various solid malignancies. It was found to have an exceptionally pervasive effect in head and neck carcinomas and to lead to a relative risk of death increased by 75% compared to non-anemic cancer patients \[[@pone.0205712.ref027]\]. It was recently shown that preoperatively low hemoglobin levels decrease OS in a study of 167 head and neck cancer patients undergoing tumor resection followed by free flap reconstruction between July 2007 and February 2013 \[[@pone.0205712.ref028]\]. As demonstrated by Chau *et al*., preoperative hemoglobin concentrations \<12 g/dL increased recurrence rates and survival in a retrospective study of 520 patients who underwent primary resection of various head and neck malignancies \[[@pone.0205712.ref029]\].

The existence of far-reaching effects of blood transfusion on the immune system is no longer subject of discussion. The condition termed transfusion-related immune modulation is well established in transfusion medicine and its immunosuppressive component was once therapeutically exploited to reduce allograft rejection after kidney transplantation \[[@pone.0205712.ref004], [@pone.0205712.ref030]\]. This very effect is suspected to increase the risk of disease recurrence and decreased survival in surgical oncology. Accordingly, PBT was shown to be associated with higher recurrence rates and decreased survival in head and neck cancer. Taniguchi *et al*. retrospectively analyzed 105 patients with stage III and IVa oral cavity squamous cell carcinomas who underwent tumor resection and neck dissection between January 1990 and December 1998. Overall survival of patients who received ≥3 units was significantly lower \[[@pone.0205712.ref031]\]. This finding was later confirmed by Szakmany *et al*. in a study of 559 patients with oral cavity and oropharyngeal squamous cell carcinomas undergoing primary surgery between 1992 and 2002 \[[@pone.0205712.ref032]\]. Danan and colleagues also supported the threshold of ≥3 units of packed red blood cells transfusion. Patients who received this amount had a significantly increased risk of death \[[@pone.0205712.ref028]\]. In the study by Chau and colleagues, PBT was associated not only decreased survival but also with higher recurrence rates \[[@pone.0205712.ref029]\]. The results of the latter studies were opposed by Fenner and colleagues who retrospectively analyzed the cases of 223 patients with oral squamous cell carcinoma undergoing primary surgery between July 1998 and June 2002. According to their results, transfusion of \>4 units of packed red blood cells did not influence overall survival \[[@pone.0205712.ref033]\].

Interestingly, transfusion rates vastly differed between these studies. While Taniguchi and colleagues report that 61.0% of their patients received one or more PBT \[[@pone.0205712.ref031]\], this rate was 77.1% \[[@pone.0205712.ref032]\], 82.0% \[[@pone.0205712.ref028]\], 37.9% \[[@pone.0205712.ref029]\] and 97.3% \[[@pone.0205712.ref033]\] in other studies cited.

In our study both, peroperative anemia and PBT had little impact on DFS. In contrast, both factors significantly decreased OS in univariate analysis, even though tumor localization and perineural invasion of cancer cells emerged as most significant in multivariate analysis ([Table 2](#pone.0205712.t002){ref-type="table"}). These results lead to the question whether the administration of PBT increased mortality, or whether patients who received PBT were more likely to decease anyway. Because in our study PBT was more frequently needed by older patients, patients in worse physical conditions, anemic patients, patients with p16-negative and more advanced pT- and pN-stage HNSCC, we suggest that these factors contributed to the significance of PBT in univariate analysis of OS. Also, patients who received PBT died significantly more often of cancer-unrelated causes (38.9% vs. 28.1%; p = 0.031). Nevertheless, subgroup analyses revealed the profound negative impact of PBT on OS in patients \<60 years of age, non-anemic patients, patients with p16-postive HNSCC and early pT- and pN-stage carcinomas, too ([Table 3](#pone.0205712.t003){ref-type="table"}). Notably, subgroup analyses cannot be interpreted as a substitute of multivariate analyses.

There is an ongoing discussion regarding adequate triggers for red blood cells transfusion. Two major transfusion strategies can be discerned. According to the liberal transfusion policy, the threshold hemoglobin concentration is 9--10 g/dL. The restrictive transfusion strategy\`s threshold is 7--8 g/dL \[[@pone.0205712.ref022]\]. In a recent review for the Cochrane collaboration, Carson and colleagues conclude that there is good evidence that transfusions with allogeneic red blood cells can be avoided in most hospitalized patients with hemoglobin concentrations above 7 g/dL to 8 g/dL \[[@pone.0205712.ref034]\]. The policy of both, the Department of Anesthesiology and the Department of Otorhinolaryngology, Head and Neck Surgery in our clinic is to avoid PBT for head and neck cancer patients until a threshold of \<7 g/dL is reached. Thus, different transfusion strategies are most likely the reason for vastly differing transfusion rates. Our cohort had the lowest transfusion rate of all studies cited. Because of the retrospective design of this study a selection bias cannot be excluded, but the calculated transfusion rate of 18.4% corresponds with the clinical experience of the authors.

The WHO defines anemia primarily as insufficient number of red blood cells. Applying this very definition of anemia, not only low hemoglobin concentrations as a surrogate for oxygen-carrying capacity, almost as many patients (75) were classified anemic as were found to be anemic according to hemoglobin levels (79). Patients classified anemic based on RBC only show a significantly worse survival compared to non-anemic patients (p\<0.001; [Fig 2](#pone.0205712.g002){ref-type="fig"}). The vast majority of clinical studies on the impact of anemia in HNSCC are based on hemoglobin concentrations \[[@pone.0205712.ref028], [@pone.0205712.ref029], [@pone.0205712.ref035]--[@pone.0205712.ref037]\]. Therefore, an important finding of our study is that anemia as an independent prognostic factor in surgical oncology of the head and neck should be defined as low hemoglobin concentration as well as low RBC.

Summary {#sec012}
-------

Anemic conditions of HNSCC patients are a common paraneoplastic syndrome of various causes. Unlike all other factors analyzed for their impact on survival in this study, pre- and perioperative anemia is a potential aim of therapeutic intervention. Even though in our study, perioperative blood transfusion was needed more frequently by older patients in worse physical condition suffering from more advanced stage HNSCC, subgroup analyses demonstrate the negative impact of PBT in younger patients with early stage HNSCC, too. Therefore, we conclude that a restrictive transfusion policy is appropriate in surgical oncology of HNSCC. Despite the devastating impact of anemia in HNSCC, we suggest that anesthesiologists and surgeons should restrain from correcting anemic conditions by PBT unless urgently needed.
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